Background and objective: Although both nonalcoholic fatty liver disease (NAFLD) and lung function are known to be associated with metabolic syndromes, few studies have evaluated the relationship between NAFLD and lung function. Our population-based study was conducted to investigate whether NAFLD, diagnosed by elevation of liver enzymes without other chronic liver disease or heavy alcohol drinking, is associated with lung function. Methods: A survey design analysis was performed using national representative data of health and nutritional status of civilians in Korea (Korean National Health and Nutrition Examination Survey, KNHANES) between 2010 and 2012. The criteria for NAFLD diagnosis was elevated serum alanine aminotransferase (ALT) without other chronic liver disease or heavy alcohol drinking. Covariate-adjusted linear regression analyses and poststratification adjustments to the survey weights based on the propensity scores (PS) were conducted to evaluate the association of NAFLD and lung function, including the forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC). Results: A total of 7417 subjects were included in this analysis. NAFLD was significantly associated with a lower FVC among males as determined by both the covariateadjusted linear regression analysis (P < 0.01 in all multivariable models) and PS analysis (P = 0.007). In the PS analysis, NAFLD was significantly associated with lower FEV 1 (P = 0.044) among males. Among females, NAFLD was associated with a lower FVC according to the linear regression analysis; this finding was not verified with the PS analysis. Conclusion: NAFLD was significantly associated with lower lung function and this relationship was more prominent among males.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases, and the estimated prevalence is 20-35% among the general population. 1 NAFLD is known to be closely associated with metabolic conditions, including insulin resistance, abdominal obesity, dyslipidaemia and type 2 diabetes, and is thus regarded as the hepatic manifestation of the metabolic syndrome. [2] [3] [4] An increasing number of studies suggest that NAFLD is associated with cardiovascular disease and chronic kidney disease independent of the established cardiovascular risk factors or metabolic syndromes. 5, 6 It is well known that lung function is mainly associated with physical attributes, including ethnicity, age, sex, height and weight. 7, 8 However, the relationship between lung function and metabolic conditions has only recently been highlighted. For example, diabetes and higher fasting glycaemic levels are associated with lower forced expiratory volume in 1 s (FEV 1 ) and lower
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Both non-alcoholic fatty liver disease (NAFLD) and lung function are known to be associated with metabolic syndromes; however, few studies have evaluated the relationship between NAFLD and lung function. This population-based study showed that NAFLD was significantly associated with lower lung function; this relationship was more prominent among males.
forced vital capacity (FVC). 9 FEV 1 and FVC are also inversely related to insulin resistance, 10, 11 and lung function impairment is independently related to metabolic syndrome. 12 Additionally, waist circumference has been reported to be inversely associated with lung function. 13 However, only a few studies have investigated the association between NAFLD and lung function; those studies 14, 15 used covariate-adjusted regression analyses, which control for variables in a linear fashion and insufficiently remove selection bias. Propensity score (PS) methodology could overcome this limitation. 16 Additionally, although the effects on lung function could be modified by ethnicity, 17 only one study (which included only males) has evaluated the relationship between NAFLD and lung function in the Asian population. 15 Therefore, we investigated whether NAFLD (diagnosed as elevated liver enzyme or hepatic steatosis index (HSI) 18 without other chronic liver diseases or heavy alcohol drinking) is associated with lung function in a large-scale, population-based study. We used both linear regression and PS analyses (with post-stratification adjustments to the survey weights based on the PS).
METHODS

Study subjects
The Korean National Health and Nutrition Examination Survey (KNHANES) is a national representative study designed to assess the health and nutritional status of civilians in Korea. KNHANES V was performed from 2010 to 2012. KNHANES uses a complex, multistage probability sample design. The sample represents the total, non-institutionalized civilian population of Korea. 19, 20 The sample is based on data from the Korean Statistical Office census and contains 3800 households from 576 randomly selected survey areas, which are drawn annually from a census of the population. The number selected is proportional to the size of each area. Trained interviewers administer questionnaires regarding various health-related issues. For this study, we initially included 9281 subjects aged 20-90 years who underwent both liver enzyme testing and spirometry. Subjects with other potential causes of chronic liver disease were excluded as follows: 1442 subjects with excessive alcohol drinking (>30 g/day for men and >20 g/day for women) 1 ; 384 subjects with the hepatitis B virus (as determined by the presence of the hepatitis B surface antigen); 23 subjects with a history of chronic hepatitis C; and 15 subjects with a history of liver cirrhosis based on the past medical history. The final analysis included 7417 subjects (Fig. 1 ). Data were obtained from the KNHANES database. Exemption from informed consent was granted by the Institutional Review Board Committee of our hospital as this study utilized data publically available through KNHANES (IRB No. 1401-047-547).
Spirometry
Spirometry was performed by trained medical personnel using dry rolling-seal spirometers (SensorMedics, Model 2130, Yorba Linda, CA, USA), which met the criteria of the American Thoracic Society/European Respiratory Society (ATS/ERS). 21 The results were acceptable if they satisfied the following criteria: (i) extrapolated volume <5% of the FVC or 0.15 L (whichever was less); (ii) time for peak expiratory flow rate was >120 ms; (iii) no cough or glottis closure during the spirometric examination that influenced the measurement; (iv) no early termination or cut-off, defined as any volume change that could not be identified in at least 1 s or a reasonable exhalation time; (v) no Valsalva manoeuvre or cut-off during the examination; (vi) no leak; (vii) unobstructed mouthpiece; and (viii) maximal subject effort throughout. Reproducibility was defined as both the difference between the largest and smallest FVC and the difference between the largest and smallest FEV 1 of <150 mL. 22 
Definition of NAFLD and covariates
Patients were diagnosed with NAFLD if they had a serum alanine aminotransferase (ALT) level > 40 IU/L and did not have excessive alcohol consumption (defined as >30 g/day for men and >20 g/day for women), chronic hepatitis B (determined by the presence of the hepatitis B surface antigen), chronic hepatitis C or other history of liver cirrhosis based on the past medical history. To strengthen our finding, we additionally defined NAFLD by HSI as a sensitivity analysis. HSI was calculated as follows: HSI = 8 × (ALT/AST ratio) + BMI (+2, if female; +2, if diabetes mellitus), where AST is aspartate aminotransferase. 18 NAFLD was defined when HSI was more than 36.
Based on subject-recorded questionnaires and medications, smoking was measured by pack-years, and alcohol intake was calculated. Elevated blood pressure was defined by taking antihypertensive medications or having a measured blood pressure ≥ 130/85 mm Hg. Hyperglycaemia was defined as taking any glucoselowering agents or a fasting glucose ≥ 110 mg/dL. Diabetes was defined as taking any glucose-lowering agents or a fasting glucose ≥ 126 mg/dL. 23 Body mass index (BMI) was calculated using height and weight according to the formula: BMI = weight (kg)/height (m 2 ). Metabolic syndrome was defined according to the criteria of the National Cholesterol Education Program Adult Treatment Panel III, except abdominal obesity. 24 Abdominal obesity was defined using Asian guidelines. 25 Study subjects were diagnosed as having metabolic syndrome if they had three or more of the following characteristics: waist circumference > 90 cm for men or > 80 cm for women; systolic blood pressure/diastolic blood pressure ≥ 130/85 mm Hg; triglycerides (TG) ≥ 150 mg/dL; fasting blood glucose level ≥ 110 mg/dL or medical therapy for hyperglycaemia; high-density lipoprotein (HDL) cholesterol level of <40 mg/dL for men and <50 mg/dL for women. 24 
Statistical analysis
As the KNHANES data are collected using a complex sampling design, the survey weights are provided. 19, 20 Survey sample weights were used in all analyses to produce estimates that were representative of the noninstitutionalized population. First, we investigated the association between NAFLD and lung function, including FEV 1 and FVC. A linear regression analysis was performed. Model 1 included age, height and smoking status as covariates. Model 2 included model 1 covariates and the presence of metabolic syndrome. Model 3 included all the variables in order to construct PS which is described below. Second, as an alternative to linear regression, we modified the PS subclassification method for complex survey data. The PS of NAFLD was derived from a logistic regression analysis in which multiple variables, including socio-economic status (region, income, education level, occupation, marital status, type of healthcare insurance and having or not having private insurance); demographic factors (age, height, weight, waist circumference and BMI); smoking pack-years; HDL; glucose; and TG. PS was calculated separately for males and females, and the data were subclassified into five strata based on the quintiles of the estimated PS. A new survey weight was then calculated with post-stratification adjustments to the original survey weight. 26, 27 Variables that differed between the NAFLD and non-NAFLD groups were identified using the new weight. For unbalanced covariates, additional adjustments were performed.
RESULTS
Among 9281 subjects who underwent both serum liver enzyme testing and spirometry, 1864 were excluded due to either a history of chronic liver disease or heavy alcohol history. In total, 7417 subjects were included in our analysis. The demographic and laboratory findings for the study subjects are presented in Table 1 . Approximately 7% (6.6%) of subjects were identified as having NAFLD (9.9% of males and 4.6% of females). The mean FEV 1 and FVC values of the study subjects were 2.61 and 3.37 L, respectively (92.6% and 92.9% of the predicted values, respectively).
NAFLD was not significantly associated with FEV 1 in various multivariate linear regression models in either sex (except for males in multivariate model 1 in which age, height and smoking pack-years were adjusted) ( Table 2 ). However, NAFLD was significantly associated with a low FVC in both sexes even when age, height, smoking pack-years and metabolic syndrome were adjusted (P < 0.01 in multivariable models 1 and 2 among males, P < 0.05 in multivariable models 1 and 2 among females) ( Table 3) . Model 3 including all covariates used in order to construct PS showed similar results although FVC in females was not significantly associated with NAFLD (P < 0.001 in males and P = 0.103 in females). When NAFLD was defined by elevated HSI, the result was similar. NAFLD was not associated with FEV 1 (Table 2 ), but significantly associated with a low FVC (P = 0.016 for males and P = 0.002 for females in multivariate model 2 0 , Table 3 ) in both sexes. After post-stratification adjustments to the survey weights, the NAFLD and non-NAFLD groups had similar covariate distributions in both sexes (except for body weight, waist circumference, BMI and HDL in males) (Table S1 , Supplementary Information). Due to multicollinearity, one variable at a time was entered as a covariate in the regression model. BMI-adjusted models were utilized, which revealed the significant relationship between NAFLD and lower FEV 1 (P = 0.044) and FVC (P = 0.007) among males. Among males, NAFLD was significantly associated with low FEV 1 in some models; however, there were no statistically significant associations found between NAFLD and lung function among females (Table 4) .
DISCUSSION
In this study, NAFLD was significantly associated with lower FVC among males in both the covariate-adjusted regression and PS-matching analyses. NAFLD was significantly associated with lower FEV1 in BMI-adjusted PS models in males. Among females, NAFLD was associated with a lower FVC, although this relationship was not verified by the PS-matching analysis.
A previous study 15 showed an inverse relationship between NAFLD and decreased FEV 1 and FVC in men. Another recent study using NHANES III data 14 also reported that FEV 1 and FVC were inversely associated with the degree of NAFLD, and the restrictive lung pattern was significantly associated with NAFLD. Although that study included subjects with various ethnicities, Asians were not included. We included Koreans of both sexes using nationwide survey data and applied various multivariate models and PS to clarify the relationship between NAFLD and lung function in both sexes. The present study showed that the relationship between NAFLD and lower lung functions was predominant in males; although we could not uncover a mechanism, the relationship between NAFLD and lower lung function might be explained in several ways. First, NAFLD is associated with insulin resistance throughout the body, 28 including skeletal muscle. 29 Insulin resistance is associated with skeletal muscle weakness, it reduces glucose utilization and induces abnormal fat metabolism in muscle, which may impair mitochondrial adenosine triphosphate production, thus reducing muscle strength. 10, 30, 31 Forced inspiration during spirometry requires respiratory skeletal muscle contraction. Thus, respiratory muscle dysfunction may cause abnormal ventilatory function. 32 Indeed, several studies have reported on the role of insulin resistance in reduced lung function. 33, 34 Second, hormones related to metabolism and systemic inflammation, such as adiponectin, may be related to reduced lung function and NAFLD. Adiponectin is widely associated with glucose regulation and fatty acid oxidation. Adiponectin also has antiinflammatory effects via attenuation of tumour necrosis factor-alpha (TNF-a)-mediated inflammatory responses, inhibition of proinflammatory cytokines, such as interleukin-6 (IL-6), and induction of antiinflammatory cytokines, such as IL-10. 35, 36 According to previous studies, adiponectin levels are independently associated with lung function decline regarding FEV 1 and FVC 37, 38 ; adiponectin has also been associated with NAFLD and its progression. 39, 40 In our study, the association between NAFLD and impaired lung function was not significant among females. The differences between the sexes could be related to hormonal effects. Oestrogen has beneficial effects on insulin sensitivity through direct effects on glucose homeostasis, is involved in body composition and adipose tissue metabolism and has proinflammatory effects. 41 In contrast, androgens can significantly reduce muscle insulin sensitivity in rat models 42 and testosterone may also decrease adiponectin levels. 43 Unfortunately, in our study, we could not evaluate insulin resistance in respiratory muscle, adipokine levels or health-related fitness to verify these hypotheses.
Our study had several strengths, it was based on nationwide survey data that are representative of the Korean population. Additionally, to avoid an inappropriate analysis of survey data, which can lead to biased estimates and overstated significance levels, 44 this study used a survey design analysis. Second, we used both covariate-adjusted regression and PS stratification analyses to evaluate the association between lung function and NAFLD; both analyses revealed similar results. Third, we included various confounding factors, including age, height, smoking status and presence of the metabolic syndrome. The metabolic syndrome is closely associated with NAFLD. 4, 45 Details regarding smoking status, one of the most important factors affecting lung function, were collected and defined as pack-years. These methods could minimize selection bias in an observational study and could elucidate the impacts of NAFLD per se on lung function more adequately.
We should also acknowledge the limitations of this study. First, we diagnosed fatty liver disease based on serum ALT levels or HSI instead of ultrasonography or liver biopsies. However, ALT levels are closely associated with NAFLD and intrahepatic TG contents 46, 47 and several population-based studies have diagnosed NAFLD based on elevated serum ALT levels. 48, 49 In addition, we strengthened our study by also defining NAFLD by HSI, which is a well-validated screening tool for NAFLD. 18 Second, we did not clarify the mechanisms underlying the association between NAFLD and lung function decline, although we provided some hypotheses. Further studies evaluating insulin resistance, muscle strength and hormone levels are needed to investigate the underlying mechanisms between the association of NAFLD and lung function. Third, NAFLD-related advanced hepatic fibrosis might be associated with lung function. However, we could not ALT, alanine aminotransferase; FVC, forced vital capacity; HSI, hepatic steatosis index; NAFLD, non-alcoholic fatty liver disease; PS, propensity score.
analyse these interactions because of the small number of NAFLD cases with moderate to severe fibrosis based on FIB-4 index 50 (data not shown). This is due to characteristics of study subjects considering that KNHANES data are from general population.
In conclusion, this study showed that NAFLD defined by serum ALT levels or HSI was significantly associated with lower lung function, and this relationship was more prominent among males. 
